Relay Therapeutics Inc logo

RLAY

Relay Therapeutics Inc

$18.76

Earnings Summary

Revenue
$0.67Mn
Net Profits
$-60.83Mn
Net Profit Margins
-9134.08%

Highlights

Revenue:

Relay Therapeutics Inc’s revenue jumped +Inf% since last year same period to $0.67Mn in the Q3 2021. On a quarterly growth basis, Relay Therapeutics Inc has generated -21.09% fall in its revenue since last 3-months.

Net Profits:

Relay Therapeutics Inc’s net profit fell -68.62% since last year same period to $-60.83Mn in the Q3 2021. On a quarterly growth basis, Relay Therapeutics Inc has generated 68.55% jump in its net profits since last 3-months.

Net Profit Margins:

Relay Therapeutics Inc’s net profit margin jumped NaN% since last year same period to -9134.08% in the Q3 2021. On a quarterly growth basis, Relay Therapeutics Inc has generated 60.14% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Relay Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.73
EPS Estimate Current Year
-0.73

Highlights

EPS Estimate Current Quarter:

Relay Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.73 - a -3.13% fall from last quarter’s estimates.

EPS Estimate Current Year:

Relay Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.73.

Key Ratios

Key ratios of the Relay Therapeutics Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-0.71
Return on Assets (ROA)
-0.2
Return on Equity (ROE)
-0.37

Highlights

Earning Per Share (EPS):

Relay Therapeutics Inc’s earning per share (EPS) jumped 66.19% since last year same period to -0.71 in the Q2 2022. This indicates that the Relay Therapeutics Inc has generated 66.19% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Relay Therapeutics Inc’s return on assets (ROA) stands at -0.2.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Relay Therapeutics Inc’s return on equity (ROE) stands at -0.37.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-08-04
-0.63
-0.71
-13.22%
2022-05-05
-0.62
-0.57
7.81%

Company Information

Relay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer. Relay Therapeutics serves customers in the United States.

Organisation
Relay Therapeutics Inc
Headquarters
399 Binney Street, Cambridge, MA, United States, 02139
Employees
320
Industry
Health Technology
CEO
Sanjiv K. Patel

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*